BRCA1 and p53 regulate critical prostate cancer pathways

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 3, 2013, Pages 233-238

  De Luca, P ^a   Moiola, C P ^a   Zalazar, F ^a   Gardner, K ^b   Vazquez, E S ^a   De Siervi, A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

BRCA1; DNA damage; GADD153; p53

Indexed keywords

BETA CATENIN; BLOOM SYNDROME HELICASE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; FIBRONECTIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; LUCIFERASE; PROTEIN P53; PROTEIN PATCHED 1; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; VIMENTIN;

ACTIN B GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA CATENIN GENE; BLM GENE; CCNB2 GENE; CELL CYCLE REGULATION; CELL STRAIN LNCAP; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYCLIN D1 GENE; DDB2 GENE; DNA DAMAGE; E CADHERIN GENE; ENZYME ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FEN1 GENE; FIBRONECTIN GENE; GADD153 GENE; GADD45A GENE; GENE; GENE EXPRESSION; GLI1 GENE; H3F3B GENE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; P21 WAF1 CIP1 GENE; PATCH1 GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHH GENE; SLUG GENE; SNAIL GENE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; VIMENTIN GENE; WESTERN BLOTTING;

ANIMALS; BRCA1 PROTEIN; CELL CYCLE; CELL LINE, TUMOR; DNA DAMAGE; HEDGEHOGS; HETEROGRAFTS; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR CHOP; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84882451084     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.12     Document Type: Article

References (31)

1. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
2. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18: 477-485.
3. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2: a001008.
4. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
5. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1- mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343: 692-695.
6. Douglas JA, Levin AM, Zuhlke KA, Ray AM, Johnson GR, Lange EM et al. Common variation in the BRCA1 gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007; 16: 1510-1516.
7. Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010; 16: 2115-2121.
8. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 2007; 104: 12111-12116.
9. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108: 171-182.
10. De Luca P, Vazquez ES, Moiola CP, Zalazar F, Cotignola J, Gueron G et al. BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer. Mol Cancer Res 2011; 9: 1078-1090.
11. De Siervi A, De Luca P, Byun JS, Di LJ, Fufa T, Haggerty CM et al. Transcriptional autoregulation by BRCA1. Cancer Res 2010; 70: 532-542.
12. Smith JL, Freebern WJ, Collins I, De Siervi A, Montano I, Haggerty CM et al. Kinetic profiles of p300 occupancy in vivo predict common features of promoter structure and coactivator recruitment. Proc Natl Acad Sci USA 2004; 101: 11554-11559.
13. Xu CF, Chambers JA, Solomon E. Complex regulation of the BRCA1 gene. J Biol Chem 1997; 272: 20994-20997.
14. De Siervi A, De Luca P, Moiola C, Gueron G, Tongbai R, Chandramouli G et al. Identification of new Rel/NFkB regulatory networks by focused genome location analysis. Cell Cycle 2009; 8: 13.
15. MacLachlan TK, Somasundaram K, Sgagias M, Shifman Y, Muschel RJ, Cowan KH et al. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem 2000; 275: 2777-2785.
16. Anand S, Chakrabarti E, Kawamura H, Taylor CR, Maytin EV. Ultraviolet light (UVB and UVA) induces the damage-responsive transcription factor CHOP/gadd153 in murine and human epidermis: evidence for a mechanism specific to intact skin. J Invest Dermatol 2005; 125: 323-333.
17. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9: 95-107.
18. Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 2009; 69: 3625-3633.
19. Manie E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009; 69: 663-671.
20. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85: 1657-1669.
21. Moiola C, De Luca P, Cotignola J, Gardner K, Vazquez E, De Siervi A. Dynamic coregulatory complex containing BRCA1, E2F1 and CtIP controls ATM transcription. Cell Physiol Biochem 2012; 30: 596-608.
22. Agiostratidou G, Hulit J, Phillips GR, Hazan RB. Differential cadherin expression: potential markers for epithelial to mesenchymal transformation during tumor progression. J Mammary Gland Biol Neoplasia 2007; 12: 127-133.
23. Mitselou A, Batistatou A, Nakanishi Y, Hirohashi S, Vougiouklakis T, Charalabopoulos K. Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites. Histol Histopathol 2010; 25: 1257-1267.
24. Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 2010; 9: 179.
25. Hudson LG, Zeineldin R, Stack MS. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis 2008; 25: 643-655.
26. Paredes J, Correia AL, Ribeiro AS, Milanezi F, Cameselle-Teijeiro J, Schmitt FC. Breast carcinomas that co-express E- and P-cadherin are associated with p120- catenin cytoplasmic localisation and poor patient survival. J Clin Pathol 2008; 61: 856-862.
27. Emadi Baygi M, Soheili ZS, Essmann F, Deezagi A, Engers R, Goering W et al. Slug/ SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. Tumour Biol 2010; 31: 297-307.
28. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008; 8: 743-754.
29. Chen M, Feuerstein MA, Levina E, Baghel PS, Carkner RD, Tanner MJ et al. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Mol Cancer 2010; 9: 89.
30. Sanchez P, Clement V, Ruiz i Altaba A. Therapeutic targeting of the Hedgehog-GLI pathway in prostate cancer. Cancer Res 2005; 65: 2990-2992.
31. Zhang J, Lipinski R, Shaw A, Gipp J, Bushman W. Lack of demonstrable autocrine hedgehog signaling in human prostate cancer cell lines. J Urol 2007; 177: 1179-1185.